Abstract:609 Background: Despite advances, effective treatments are needed for patients (pts) with metastatic urothelial carcinoma (mUC). Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) specific for Nectin-4 that is approved as monotherapy and in combination with pembrolizumab in patients who are cisplatin-ineligible. Cabozantinib (cabo) is a multi-tyrosine kinase that inhibits VEGF, MET and AXL with activity in heavily pretreated mUC. Preclinical data suggests antiangiogenic agents may increase ADC penetration of tumor cells, potentially leading to therapeutic synergy. We report safety and preliminary efficacy data from the dose escalation cohort of an ongoing phase I/Ib trial investigating cabo in combination with EV in mUC. Methods: This is a phase I/Ib, open label, single arm, trial at the Winship Cancer Institute of Emory University (NCT04878029). Pts with histologically confirmed mUC who received or were ineligible for platinum chemotherapy and a checkpoint inhibitor are eligible. The phase I dose escalation is a traditional 3+3 design exploring cabo 20 or 40 mg daily with standard dose EV (1.25 mg/kg on days 1, 8, and 15 of a 28-day cycle). The dose expansion cohort is currently enrolling. The primary endpoint of the phase I cohort was safety and tolerability to determine the RP2D. Key secondary objective is preliminary evidence of efficacy via objective response rate (ORR) per RECIST v1.1. Results: As of the 22 September 2023 data cut, 6 pts with mUC have been treated. Three pts were enrolled at the cabo 20 mg and 40 mg dose levels, respectively. All are male with median age of 69 (61-85). 4 of 6 patients (66.7%) are white. One serious adverse event (SAE) occurred in the 20 mg cohort (dehydration) and 3 SAEs occurred at the 40 mg dose (neutropenia, acute kidney injury, superior vena cava syndrome); the neutropenia was the singular grade 4 AE. While this represented the sole dose-limiting toxicity of dose escalation, cabo 20 mg daily was selected as the RP2D based on clinical judgment regarding longer-term tolerability. Only one pt in the 40 mg cohort remains on the initial dose. The most common treatment-related AEs are ALT elevation, hypophosphatemia, rash (66%), fatigue, mucositis, AST elevation, hypomagnesemia, eye irritation, hand-foot syndrome, and anorexia (50%). Five pts had a grade 3 AE (83%); the most common were fatigue (33%) and AKI (33%). The ORR was 83% with each of the 5 of 6 responders experiencing a partial response. The median target lesion reduction was 49.7% (31.8-100). Conclusions: These preliminary data suggest that the combination of EV and cabo 20 mg daily is safe and tolerable with adverse events previously seen with each agent. Encouraging early evidence of activity has been observed based on response rates. Enrollment of mUC pts into dose expansion with cabo 20 mg daily continues and further results including long-term outcomes and correlatives are forthcoming. Clinical trial information: NCT04878029 .

A Phase II Study of Cabozantinib (cabo) Alone or in Combination with Trastuzumab (T) in Patients (pts) with Breast Cancer Brain Metastases (BCBM).

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).

A Single-Arm Phase II Study of Cabozantinib and Atezolizumab in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (R/M ESCC) Who Failed Platinum-Based Chemotherapy.

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib

Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.

Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer

A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors

60 CONTACT-01: Efficacy and Safety from a Phase III Study of Atezolizumab (atezo) + Cabozantinib (cabo) Vs Docetaxel (doc) Monotherapy in Patients (pts) with Metastatic NSCLC (mnsclc) Previously Treated with Checkpoint Inhibitors and Chemotherapy

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

Interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

Phase II trial of cabozantinib (cabo) plus durvalumab (durva) in chemotherapy refractory microsatellite stable (MSS) patients with advanced gastric and esophageal (G/E) adenocarcinoma: CAMILLA G/E cohort results.

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers